ERBB2 and cancer: Some major clinical results have been obtained following the discovery that certain gene alterations, such as activating KRAS or NRAS point mutations, BRAFV600E mutation, HER2 gene amplification or the MSI high (MSI-H) status may characterize specific subgroups of patients that could be treated with selective anti-cancer therapies [21, 22].